- Browse by Author
Browsing by Author "Hong, Gloria J."
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity(Science Direct, 2021-05-06) Hong, Gloria J.; Stinnett, Sandra S.; Freedman, Sharon F.; Wallace, David K.; Prakalapakorn, S. Grace; Ophthalmology, School of MedicineGuidelines on managing infants after initial anti-vascular endothelial growth factor (VEGF) treatment (eg, bevacizumab) for retinopathy of prematurity (ROP) are limited. We found that following initial bevacizumab treatment for ROP, prophylactically lasering infant eyes before hospital discharge reduced the number and duration of outpatient ROP screening examinations compared with following infants, per current United States (US) ROP screening guidelines.Item Quantitative comparison of blood vessel changes after treatment of retinopathy of prematurity with laser versus bevacizumab(Elsevier, 2022-12) Wang, Weiliang; Hong, Gloria J.; Stinnett, Sandra S.; Freedman, Sharon F.; Wallace, David K.; Prakalapakorn, S. Grace; Ophthalmology, School of MedicineCurrent therapies for treatment-indicated (type 1) retinopathy of prematurity mainly consist of laser photocoagulation and intravitreal anti-vascular endothelial growth factor (eg, bevacizumab) injection. The first visible signs of acute-phase regression are typically vascular, including decreased plus disease. Using a semiautomated computer program, we quantitatively compared posterior pole vascular changes following treatment with laser versus bevacizumab and found that in the first month following treatment, vascular dilation and tortuosity significantly decreased following either treatment modality, but tortuosity decreased earlier and faster after bevacizumab.Item Quantitatively comparing weekly changes in retinal vascular characteristics of eyes eventually treated versus not treated for retinopathy of prematurity(Elsevier, 2021) Hong, Gloria J.; Koerner, Jagger C.; Weinert, Marguerite C.; Stinnett, Sandra S.; Freedman, Sharon F.; Wallace, David K.; Riggins, J. Wayne; Gallaher, Keith J.; Prakalapakorn, S. Grace; Ophthalmology, School of MedicinePurpose To quantitatively compare retinal vascular characteristics over time in eyes eventually treated versus not treated for retinopathy of prematurity (ROP), using ROPtool analysis of narrow-field retinal images. Methods This longitudinal study used prospectively collected narrow-field retinal images of infants screened for ROP, prior to treatment, if needed. Images were analyzed using a methodology that combines quadrant-level measures from several images of the same eye. For the longitudinal analysis, one examination per postmenstrual age (PMA) was included per eye. We compared the following ROPtool indices and their change per week between eyes eventually treated versus not treated for ROP: tortuosity index (TI), dilation index (DI), sum of adjusted indices (SAI), and tortuosity-weighted plus (TWP). Analysis was performed on three levels: eye (mean value/eye), quadrant (highest quadrant value/eye), and blood vessel (highest blood vessel value/eye). Results Of 832 examinations (99 infants), 745 images (89.5%) had 3-4 quadrants analyzable by ROPtool. On the eye level, ROPtool indices differed between eyes eventually treated versus not treated at PMA of 33-35 and 37 weeks for TI, SAI, and TWP, and at PMA of 33-34 and 37 weeks for DI (P ≤ 0.0014), and change per week differed between eyes eventually treated versus not treated only for SAI at PMA of 32 weeks (P < 0.001). Conclusions Quantitative analysis of retinal vascular characteristics using ROPtool can help predict eventual need for treatment for ROP as early as 32 weeks PMA. ROPtool index values were more useful than change in these indices to predict eyes that would eventually need treatment for ROP.